Aquacel Hypersensitivity Dressing in TJAs
| 대상 질환 | Contact Allergic Dermatitis, Adverse Skin Reaction |
|---|---|
| 임상 단계 | 4상 |
| 스폰서 | Rush University Medical Center |
| 상태 | 완료 |
| 참여자 수 | 457 명 |
| 중재(약물) | Aquacel dressing |
| 시작일 | 2023년 6월 18일 |
| 완료일 | 2024년 11월 1일 |
| 결과 공개일 | 2026년 8월 4일 |
요약
The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
Number of Participants With Contact Allergic Dermatitis or Adverse Skin Reaction at 2 Weeks Post Surgery
| Arthroplasty-naïve Aquacel Group | 5 Participants |
|---|---|
| Prior Aquacel Group | 3 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
- BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital